AZOVA and Ellume provide travelers with highly accurate result and secure, shareable digital record of tests and vaccination status via smartphone
– Cheryl Lee Eberting, MD, CEO and Founder of AZOVA
ALPINE, UT, UNITED STATES, July 1, 2021 /EINPresswire.com/ – AZOVA inc., creator of the world’s most comprehensive digital health network for COVID-19 testing and vaccine management, and Ellume, the company that will market the first over-the-counter COVID-19 rapid home test, today announced a partnered with Alaska Airlines to provide its passengers with quick and convenient in-home testing. the Ellume COVID-19 home test and AZOVA video observation service provide Alaska Airlines travelers with more accessible testing options when traveling internationally.
This convenient service will allow returning travelers to the United States to easily take a rapid COVID-19 antigen test with video observation for verification that meets the United States Centers for Disease Control (CDC) requirements for re-entry. Testing options are currently available for U.S. residents traveling from Costa Rica, Mexico, and Canada.
“We love taking our customers to great places to relax and explore, including overseas,” said Amber Simonsen, director of customer product delivery at Alaska Airlines. “We want the return to the United States to be as smooth and stress-free as possible. This simple and affordable testing solution gives our customers more flexibility to perform COVID-19 testing anywhere you can make a video call. ”
“AZOVA is dedicated to reopening the world to safe travel,” said Cheryl Lee Eberting, MD, CEO and Founder of AZOVA. “We are excited to be working with our colleagues at Alaska Airlines and Ellume to present the most convenient, affordable, and straightforward way for travelers to get tested for COVID on a return trip to the United States. AZOVA’s Ellume COVID 19 Home Test Kit with Video Observation is transforming reopening strategies around the world. “
“As the pace of international travel accelerates, COVID-19 testing continues to be a critical step towards managing the spread of the virus and providing peace of mind for travelers,” said Dr. Sean Parsons, founder and CEO of Ellume. “We are delighted to partner with Alaska Airlines and AZOVA to make our Ellume COVID-19 home testing more readily available to US travelers to Costa Rica, Mexico and Canada. As the only over-the-counter rapid antigen test on the market that is licensed to provide asymptomatic and symptomatic individuals with a reliable result after a single 15-minute test, our test will be essential in ensuring safer travel experiences for everyone. . “
Ellume COVID-19 home test – Results in 15 minutes
The Ellume COVID-19 Home Test is an over-the-counter rapid self-test, which detects SARS-CoV-2 antigen in 15 minutes or less. With its patented, user-friendly nasal swab and child protection adapter, the test is suitable for adults and children 2 years and older, with or without symptoms. The Ellume test provides a very accurate result in one test and, unlike other rapid antigen tests, users do not need to administer a second test 36 hours later. The digital results are automatically transmitted to the user’s smartphone.
The Ellume COVID-19 home test and AZOVA’s video observation service are available to Alaska Airlines passengers for US $ 50. Once purchased, test kits are shipped directly to travelers. Video viewing appointments should be made at least one week in advance to ensure availability.
AZOVA COVID-19 Tests and Video Observation Services
Under current CDC requirements, travelers entering the United States must take a COVID-19 antigen test under video observation with identity verification. Once a supervisor confirms the test results, AZOVA sends a COVID ™ identifiers Health Pass by SMS or email to view and share test and vaccination results via QR code, ID or PDF.
In addition to the convenience of the Ellume COVID-19 home test, AZOVA also offers passengers traveling to certain countries outside of the United States the option of having convenient saliva or nasal RT-PCR tests at home. Results are received electronically 12 to 36 hours after the laboratory receives the sample. The FDA-cleared test has received emergency use authorization for self-administration at home and in the office or in a pharmacy. AZOVA adheres to the strictest HIPAA, SOC2, and HITRUST standards to ensure health data and COVID status is end-to-end encrypted.
More details on Alaska Airlines’ COVID-19 testing initiatives can be found at: www.alaskaair.com/content/next-level-care/covid-testing. Passengers can purchase tests through AZOVA at: https://www.azova.com/alaska/.
The Ellume COVID-19 home test has not been cleared or approved by the FDA; but was cleared by the FDA under emergency use authorization. This product has been authorized only for the detection of SARS-CoV-2 proteins, not for other viruses or pathogens, and is only authorized for the duration of the declaration of the existence of circumstances justifying the authorization. emergency use of in vitro diagnostics for detection and / or diagnosis of COVID-19 under Section 564 (b) (1) of the Federal Food, Drug and Cosmetic Act, 21 USC § 360bbb-3 (b ) (1), unless the declaration is terminated or the authorization is revoked earlier.
AZOVA is a globally connected digital health system that provides telehealth and digital health services through networks of globally connected providers, pharmacies and laboratories. AZOVA provides innovative COVID testing and vaccination solutions for employers, schools, government entities, airlines, the travel industry and the consumer. AZOVA has created the world’s first global network of truly connected labs to provide travelers with access to COVID testing anywhere in the world. For more information, visit azova.com.
Ellume is a digital diagnostics company that develops, manufactures and markets high performance connected products for healthcare professionals and consumers. It is at the forefront of the accurate, rapid and accessible testing that is integral to today’s COVID-19 response and will help ensure the world is prepared for the next infectious disease pandemic. Ellume’s primary focus is the detection of common infectious diseases that affect the world’s population in all diagnostic settings; at home, at the point of care and in the laboratory. Ellume has a global consumer health partnership with GlaxoSmithKline, a global COVID-19 and latent tuberculosis partnership with QIAGEN, and a line of professional products under its ellume • lab brand. Ellume is committed to developing high quality digital diagnostics that the world can count on in the event of a health crisis. More information is available at ellumehealth.com.
Azova company contact
David Bean, Executive Vice President of Business Development
E: [email protected]
Azova media contact
Joe Waldygo, President
E: [email protected]
Ellume media contact
LaunchSquad for Ellume
E: [email protected]